Pharmacological interaction between glycopyrronium bromide and indacaterol fumarate on the human airways tone Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016
Synergistic effects between glycopyrronium bromide and indacaterol on a muscarinic agonist-induced contraction in airway smooth muscle Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012
Effects of procaterol or salmeterol added to maintenance tiotropium therapy on small airway functions in COPD patients Source: Annual Congress 2010 - COPD: management Year: 2010
Interaction between tiotropium bromide and olodaterol in small human airways Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017
Beclomethasone, formoterol and glycopyrronium: ceiling effect in small airways of COPD patients Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020
Effects of salbutamol enantiomers on equine isolated bronchial airways Source: Annual Congress 2009 - Models of chronic airways disease and therapy Year: 2009
Interaction between tiotropium bromide and olodaterol in human bronchial smooth muscle Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
The dual PDE3/PDE4 phosphodiesterase inhibitor RPL554 produces more complete bronchodilator responses than the beta2-agonist salbutamol and the anti-muscarinic agent ipratropium bromide, alone and in combination, in guinea-pig isolated trachea Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
Adding glycopyrronium to beclomethasone/formoterol combination: synergistic effect on human small airways of COPD donors Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Differences in efficacy between formoterol and salmeterol in relaxation of the mouse trachea are accentuated by inflammatory cytokines Source: Eur Respir J 2005; 26: Suppl. 49, 370s Year: 2005
Budesonide prevents cytokine-induced decrease of the relaxant response to formoterol but not to salmeterol in mouse trachea Source: Annual Congress 2009 - Translational research/biomarkers Year: 2009
Glycopyrrolate exerts medium-duration bronchodilator activity in guinea-pig and human airways Source: Eur Respir J 2005; 26: Suppl. 49, 216s Year: 2005
Interaction between aclidinium bromide and formoterol fumarate; effects on human bronchial smooth muscle Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014
Pharmacological characterization of the mechanism of action leading to synergism between glycopyrronium bromide and indacaterol fumarate Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016
Effects of salmeterol, formoterol and placebo on pulmonary function and symptom recovery after histamine provocation in mild asthmatics Source: Eur Respir J 2004; 24: Suppl. 48, 710s Year: 2004
The acute effect of inhaled salbutamol and ipratropium on microvascular function Source: International Congress 2018 – Basic pharmacology Year: 2018
The combination therapy with inhaled tiotropium bromide and transdermal tulobuterol in COPD improves the peripheral airway function Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010
Effects of salmeterol on ciliary beat and mucus rheology in COPD patients Source: Eur Respir J 2003; 22: Suppl. 45, 78s Year: 2003
Efficacy of the device in targeting tiotropium to the small airways in COPD Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies Year: 2018
Effectiveness of glycopyrronium bromide in the treatment of small airways dysfunction Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016